Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Acts as a growth inhibitor. De plus, nous expédions Transforming Growth Factor beta Regulator 1 Anticorps (49) et et beaucoup plus de produits pour cette protéine.
Showing 6 out of 6 products:
The data provides a useful resource for exploring Myst2 and Niam essential cellular functions and should contribute to deeper understanding of organism early development and survival as well as cancer.
NIAM down-regulation in vivo results in a significant predisposition to developing benign tumors or early stage cancers.
novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2-p53 signaling
In primary B-cell lymphoma NIAM-positive cases have significant lower levels of miR-155 as compared to NIAM-negative cases, suggesting that NIAM is regulated by miR-155 in primary B-cell lymphoma.
NIAM regulates 2 critical pathways that control p53 function and are altered in human cancers, implying an important role for NIAM in tumorigenesis.
Sructure of a fragment of TBRG1 was shown to encompasses two motifs. The FYRN and FYRC regions each form part of a single folded module (the FYR domain), which adopts a novel alpha + beta fold.
NIAM is a nuclear interactor of ARF and Mdm2
Acts as a growth inhibitor. Can activate p53/TP53, causes G1 arrest and collaborates with CDKN2A to restrict proliferation, but does not require either protein to inhibit DNA synthesis. Redistributes CDKN2A into the nucleoplasm. Involved in maintaining chromosomal stability.
transforming growth factor beta regulator 1
, transforming growth factor beta regulator 1-like
, nuclear interactor of ARF and Mdm2
, nuclear interactor of ARF and MDM2
, transforming growth factor beta regulated gene 1